302 related articles for article (PubMed ID: 35547199)
1. Novel Therapies for Alport Syndrome.
Chavez E; Rodriguez J; Drexler Y; Fornoni A
Front Med (Lausanne); 2022; 9():848389. PubMed ID: 35547199
[TBL] [Abstract][Full Text] [Related]
2. The CARDINAL Trial of Bardoxolone Methyl in Alport Syndrome: When Marketing Interests Prevail over Patients Clinical Needs.
Ruggenenti P
Nephron; 2023; 147(8):465-469. PubMed ID: 36731435
[TBL] [Abstract][Full Text] [Related]
3. Alport Syndrome: Clinical Spectrum and Therapeutic Advances.
Gregorio V; Caparali EB; Shojaei A; Ricardo S; Barua M
Kidney Med; 2023 May; 5(5):100631. PubMed ID: 37122389
[TBL] [Abstract][Full Text] [Related]
4. [Alport syndrome: Hereditary nephropathy associated with mutations in genes coding for type IV collagen chains].
Heidet L; Gubler MC
Nephrol Ther; 2016 Dec; 12(7):544-551. PubMed ID: 27816395
[TBL] [Abstract][Full Text] [Related]
5. Current and Future Therapeutical Options in Alport Syndrome.
Reiterová J; Tesař V
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982595
[TBL] [Abstract][Full Text] [Related]
6. Finerenone Added to RAS/SGLT2 Blockade for CKD in Alport Syndrome. Results of a Randomized Controlled Trial with Col4a3-/- Mice.
Zhu Z; Rosenkranz KAT; Kusunoki Y; Li C; Klaus M; Gross O; Angelotti ML; Antonelli G; Cirillo L; Romagnani P; Bouteldja N; Sadr AV; Bülow RD; Boor P; Anders HJ
J Am Soc Nephrol; 2023 Sep; 34(9):1513-1520. PubMed ID: 37428955
[TBL] [Abstract][Full Text] [Related]
7. Renal, auricular, and ocular outcomes of Alport syndrome and their current management.
Zhang Y; Ding J
Pediatr Nephrol; 2018 Aug; 33(8):1309-1316. PubMed ID: 28864840
[TBL] [Abstract][Full Text] [Related]
8. Early RAAS Blockade Exerts Renoprotective Effects in Autosomal Recessive Alport Syndrome.
Uchida N; Kumagai N; Nozu K; Fu XJ; Iijima K; Kondo Y; Kure S
Tohoku J Exp Med; 2016 Nov; 240(3):251-257. PubMed ID: 27904025
[TBL] [Abstract][Full Text] [Related]
9. Searching for a treatment for Alport syndrome using mouse models.
Katayama K; Nomura S; Tryggvason K; Ito M
World J Nephrol; 2014 Nov; 3(4):230-6. PubMed ID: 25374816
[TBL] [Abstract][Full Text] [Related]
10. Autosomal dominant form of type IV collagen nephropathy exists among patients with hereditary nephritis difficult to diagnose clinicopathologically.
Imafuku A; Nozu K; Sawa N; Hasegawa E; Hiramatsu R; Kawada M; Hoshino J; Tanaka K; Ishii Y; Takaichi K; Fujii T; Ohashi K; Iijima K; Ubara Y
Nephrology (Carlton); 2018 Oct; 23(10):940-947. PubMed ID: 28704582
[TBL] [Abstract][Full Text] [Related]
11. Loss of alpha3/alpha4(IV) collagen from the glomerular basement membrane induces a strain-dependent isoform switch to alpha5alpha6(IV) collagen associated with longer renal survival in Col4a3-/- Alport mice.
Kang JS; Wang XP; Miner JH; Morello R; Sado Y; Abrahamson DR; Borza DB
J Am Soc Nephrol; 2006 Jul; 17(7):1962-9. PubMed ID: 16769745
[TBL] [Abstract][Full Text] [Related]
12. [Collagen type IV nephropathy: from thin basement membrane nephropathy to Alport syndrome].
Endreffy E; Ondrik Z; Kemény E; Vas Z; Maróti Z; Lencse G; Bereczki C; Haszon I; Túri S; Iványi B
Orv Hetil; 2005 Dec; 146(52):2647-53. PubMed ID: 16468607
[TBL] [Abstract][Full Text] [Related]
13. Identification of alpha3, alpha4, and alpha5 chains of type IV collagen as alloantigens for Alport posttransplant anti-glomerular basement membrane antibodies.
Kalluri R; Torre A; Shield CF; Zamborsky ED; Werner MC; Suchin E; Wolf G; Helmchen UM; van den Heuvel LP; Grossman R; Aradhye S; Neilson EG
Transplantation; 2000 Feb; 69(4):679-83. PubMed ID: 10708133
[TBL] [Abstract][Full Text] [Related]
14. An update on the pathomechanisms and future therapies of Alport syndrome.
Noone D; Licht C
Pediatr Nephrol; 2013 Jul; 28(7):1025-36. PubMed ID: 22903660
[TBL] [Abstract][Full Text] [Related]
15. Collagen receptors integrin alpha2beta1 and discoidin domain receptor 1 regulate maturation of the glomerular basement membrane and loss of integrin alpha2beta1 delays kidney fibrosis in COL4A3 knockout mice.
Rubel D; Frese J; Martin M; Leibnitz A; Girgert R; Miosge N; Eckes B; Müller GA; Gross O
Matrix Biol; 2014 Feb; 34():13-21. PubMed ID: 24480069
[TBL] [Abstract][Full Text] [Related]
16. Glomerular Basement Membrane Protein Expression and the Diagnosis and Prognosis of Autosomal Dominant Alport Syndrome.
Akihisa T; Sato M; Wakayama Y; Taneda S; Horita S; Hirose O; Makabe S; Kataoka H; Mori T; Sohara E; Uchida S; Nitta K; Mochizuki T
Kidney Med; 2019; 1(6):391-396. PubMed ID: 32734219
[TBL] [Abstract][Full Text] [Related]
17. Alport Syndrome: A Comprehensive Review on Genetics, Pathophysiology, Histology, Clinical and Therapeutic Perspectives.
Pedrosa AL; Bitencourt L; Paranhos RM; Leitáo CA; Ferreira GC; Simões E Silva AC
Curr Med Chem; 2021; 28(27):5602-5624. PubMed ID: 33423643
[TBL] [Abstract][Full Text] [Related]
18. RAAS inhibition and the course of Alport syndrome.
Savva I; Pierides A; Deltas C
Pharmacol Res; 2016 May; 107():205-210. PubMed ID: 26995302
[TBL] [Abstract][Full Text] [Related]
19. Glomerular basement membrane. Identification of a novel disulfide-cross-linked network of alpha3, alpha4, and alpha5 chains of type IV collagen and its implications for the pathogenesis of Alport syndrome.
Gunwar S; Ballester F; Noelken ME; Sado Y; Ninomiya Y; Hudson BG
J Biol Chem; 1998 Apr; 273(15):8767-75. PubMed ID: 9535854
[TBL] [Abstract][Full Text] [Related]
20. Non-collagen genes role in digenic Alport syndrome.
Daga S; Fallerini C; Furini S; Pecoraro C; Scolari F; Ariani F; Bruttini M; Mencarelli MA; Mari F; Renieri A; Pinto AM
BMC Nephrol; 2019 Feb; 20(1):70. PubMed ID: 30808327
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
